Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study.

By T. Chakravarty, L. Søndergaard, J. Friedman, O. D. Backer, D. Berman, K. Kofoed, H. Jilaihawi, T. Shiota, Y. Abramowitz, T. Jørgensen and 18 more. The Lancet, 2017

795 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/d638f6b2778d299fef74c8cc62a975aba3d11669

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, background): “Observational findings suggest that anticoagulant therapy reduces the incidence of subclinical thrombosis compared with dual antiplatelet therapy.(178) The results of ongoing large-scale, dedicated trials are needed to improve evidence in this field.”
• 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2020, background): “In patients with a bioprosthetic surgical or transcatheter aortic valve or bioprosthetic mitral valve who experience a stroke or systemic embolic event while on antiplatelet therapy, VKA anticoagulation, instead of antiplatelet therapy may be considered after assessment of bleeding risk.(457,458)”